US-based immuno-oncology company TapImmune launches its Phase II study of TPIV 200 to treat platinum-sensitive ovarian cancer patients.

The TPIV 200 is a multi-epitope folate receptor peptide vaccine that fights breast and ovarian cancer.

The product is composed of five peptide antigens freeze dried in a single vial, ready for injection after reconstitution and addition of granulocyte-macrophage colony-stimulating factor (GM-CSF).

The Phase II ovarian cancer study will be conducted as a double-blind, placebo controlled study intended to evaluate the benefits of using TPIV 200 in combination with standard of care chemotherapy.

TapImmune president and COO Dr John Bonfiglio said: "The opening of this study represents the fulfillment of a major 2016 milestone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We now have three clinical studies utilising TPIV 200 with approvals to enrol patients.

"The opening of this study represents the fulfillment of a major 2016 milestone."

“A fourth study in triple-negative breast cancer sponsored by the Mayo clinic with a $13.3m grant from the Department of Defence is scheduled to begin shortly.

“We believe the depth of these clinical programmes will give us an excellent understanding of how this exciting T-cell therapy can potentially be used in the treatment of both triple-negative breast and ovarian cancers."

According to the National Institute of Health, most patients with advanced ovarian cancer experience a recurrence of the disease within three years, with the initial recurrence generally being platinum-sensitive.

Platinum-sensitive recurrence describes the condition when the patient who experienced the relapse after chemotherapy can be administered with the same therapy to treat disease recurrence.

Image: TapImmune tests T-cell therapy to fight ovarian cancer. Photo: PRNewsFoto/TapImmune, Inc.